pharma · Duchenne Muscular Dystrophy · Muscular Dystrophy, Duchenne · SRPT
Sarepta Therapeutics
Sarepta Therapeutics patent portfolio — 102 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 215 First Street, Cambridge, MA 02142, US
- Employees
- 1,150
- Programs
- 46
- Drugs
- 23
- Patents
- 102
Sarepta Therapeutics patents
102 pharmaceutical patents indexed for Sarepta Therapeutics. 0 expire within 24 months.
Sarepta Therapeutics has 102 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 8697858
Antisense antiviral compound and method for treating influenza viral infection
granted -
US 8618270
Oligonucleotide analog and method for treating flavivirus infections
granted -
US 8592386
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
granted -
US 8536147
Antibacterial antisense oligonucleotide and method
granted -
US 8524676
Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
granted -
US 8501704
Immunosuppression compound and treatment method
granted
Frequently asked questions
How many patents does Sarepta Therapeutics have?
102 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Sarepta Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.